NCT02515942View on ClinicalTrials.gov

CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

September 25, 2015

Primary Completion Date

August 14, 2017

Study Completion Date

December 1, 2017

Conditions
Geographic Atrophy
Interventions
DRUG

CLG561

DRUG

LFG316

DRUG

Sham injection

Empty syringe (without a needle) placed against the eye

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
collaborator

Novartis Institutes for BioMedical Research

OTHER

lead

Alcon Research

INDUSTRY